Results 251 to 260 of about 49,999 (280)

Safety and efficacy of super-high pressure OPN balloon in patients with in-stent restenosis - an intra-coronary imaging-based observational study. [PDF]

Sci Rep
Kumaraguruparan LD, Polareddy DR, Kovvuri HR, Karthikeyan G, Malepati B, Vikash VM, Shanmugasundaram S, Sankaran R, Senguttuvan NB, Cuculi F.   +9 more
europepmc   +1 more source

Retrospective Cohort Study: Nomogram for 1-Year in-Stent Restenosis After PCI in Coronary Heart Disease. [PDF]

Risk Manag Healthc Policy
Cao XF, Chen DH, Qiu YL, Tang C, Li XL, Gu ZH.   +5 more
europepmc   +1 more source

Evaluation of Whole Blood Viscosity to Predict Stent Restenosis in Patients with Coronary Artery Disease. [PDF]

Anatol J Cardiol
Çalapkulu Y, Erdoğan M, Aslan AN, Akar N, Bulguroğlu S, Kardeşler B, Erdöl MA.   +6 more
europepmc   +1 more source

Anti-inflammatory therapy for recurrent in-stent restenosis (AI-ISR): study protocol for a prospective, randomised, open-label, multicentre clinical trial. [PDF]

BMJ Open
Yu M, Jiang Y, Song Z, Wei ZY, Tan F, Liu X, Zhang X, Zhu F, Shi Y, Huang J, Yang WX, Qian HY.   +11 more
europepmc   +1 more source

Association between stent length and number and the risk of in-stent restenosis in patients after percutaneous coronary intervention: a systematic review and meta-analysis. [PDF]

Front Cardiovasc Med
Cai C, Lu L, Ji X, Shi Z.
europepmc   +1 more source

Some of the next articles are maybe not open access.

Related searches:

In-Stent Restenosis

Interventional Cardiology Clinics, 2022
In-stent restenosis (ISR) remains a potential complication after percutaneous coronary intervention, even in the era of drug-eluting stents, and its treatment remains suboptimal. Neoatherosclerosis is an important component of the pathology of ISR and is accelerated in drug-eluting stents compared with bare-metal stents.
Kenji, Kawai, Renu, Virmani, Aloke V, Finn   +2 more
openaire   +2 more sources